Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial By admin / 02/21/2017
A phase 1/2 trial of ublituximab, a novel, glycoengineered anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab By admin / 12/16/2016
Open Label Safety Study of Ublituximab for the Treatment of Acute Neuromyelitis Optica Relapses By admin / 09/14/2016
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial. By admin / 12/08/2015
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial. By admin / 11/08/2015
a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable& Differentiated Safety Profile as a Single Agent and in Combination with a Novel Glyocengineered anti-CD20 mAb, Ublituximab in Patients with Rel/Ref CLL. By admin / 09/09/2015
a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable& Differentiated Safety Profile as a Single Agent and in Combination with a Novel Glyocengineered anti-CD20 mAb, Ublituximab in Patients with Rel/Ref CLL. By admin / 09/09/2015
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 MAB, in Combination with Ibrutinib Achieves 95% ORR in Patients with High-Risk Relapsed/Refractory CLL. By admin / 06/20/2015
Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. By admin / 06/14/2015
Safety and Activity of the Chemotherapy-free Triplet of Ublituximab, TGR-1202 and ibrutinib in Relapsed B-cell Malignancies. By admin / 06/02/2015
